Novel pretargeted radionuclide therapy for HER2-expressing cancers shows promise

IMAGE: Transversal (A), coronal (B), sagittal (C) nanoSPECT/CT images and maximum intensity projection (D) obtained 30 h after injection of pretargeted 177Lu-HP2. Tumor (indicated by arrow) was located on the abdomen…. view more 

Credit: Uppsala University, Uppsala, Sweden

RESTON, VA – In a mouse model, researchers have demonstrated that a novel, affibody-based pretargeted radionuclide therapy for HER2 (human epidermal growth factor receptor 2)-expressing cancers is non-toxic to the kidneys and improves survival. The study is reported in The Journal of Nuclear Medicine‘s July featured article of the month.

“Affibody molecules, small proteins engineered to bind to specific tumor-associated target proteins, have demonstrated excellent features for targeted molecular imaging, but their application for radionuclide therapy has so far been prevented by high renal reabsorption,” explains Vladimir Tolmachev, DMSc, professor at Uppsala University in Uppsala, Sweden. “We have now shown that the use of peptide nucleic acid (PNA)-mediated pretargeting enables a safe application of affibody molecules for radionuclide therapy.”

For the study, affibody-pretargeted lutetium-177 (177Lu)-labeled PNA was tested and evaluated in mice bearing HER2-expressing xenografts. Experimental radionuclide therapy of the mice was performed in six cycles separated by 7 days.

The data showed very rapid clearance of 177Lu-PNA from most tissues.


Article originally posted at

Click here for the full story


Privacy Policy / Terms Of Use

       Powered by MMD